Difference between revisions of "Clomipramine-duloxetine"

From Psychiatrienet
Jump to: navigation, search
Line 12: Line 12:
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
* Duloxetine is an inhibitor of CYP2D6, which metabolizes clomipramine.
 
* Duloxetine is an inhibitor of CYP2D6, which metabolizes clomipramine.
 +
{{review}}
 
}}
 
}}

Revision as of 15:39, 2 November 2015

Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine

Switch medication from clomipramine to duloxetine.

Nietinrijdenbord.png Stop clomipramine
  • Before day 1: gradually reduce dosage of clomipramine to a maximum of 50 mg/day.
  • Day 1-7: reduce dosage of clomipramine to 25 mg/day.
  • Day 8: stop administration of clomipramine.
Eenrichtingbord.png Start duloxetine
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of duloxetine in a normal dosage of 60 mg/day.
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Duloxetine is an inhibitor of CYP2D6, which metabolizes clomipramine.
  • This switch is currently being reviewed.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.